CHAPTER 11 — REFERENCES

1. Last J. *A Dictionary of Epidemiology*. 3rd ed. New York: Oxford University Press; 1995.
2. Doll R, Hill AB. Lung cancer and other causes of death in relation to smoking: a second report on the mortality of British doctors. *Br Med J* 1956;12:1071–1081.
3. Kleinbaum D, Kupper L, Morgenstern H. *Epidemiologic Research*. New York: Van Nostrand Reinhold; 1982.
4. Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. *N Engl J Med* 1997;336:1641–1648.
5. Dunn BK, Kramer BS, Ford LG. Phase III, large-scale chemoprevention trials. Approach to chemoprevention clinical trials and phase III clinical trial of tamoxifen as a chemopreventive for breast cancer—the US National Cancer Institute experience. *Hematol Oncol Clin North Am* 1998;12:1019–1036, vii.
6. Grant WB. An ecologic study of dietary and solar ultraviolet-B links to breast carcinoma mortality rates. *Cancer* 2002;94:272–281.
7. National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994, Plan and Operations Procedures Manuals (CD-ROM). Hyattsville, MD: U.S. Department of Health and Human Services (DHHS), Centers for Disease Control and Prevention; 1996.
8. Szklo M, Nieto F. *Epidemiology: Beyond the Basics*. Gaithersburg, MD: Aspen Publishers; 2000.
9. Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. *Lancet* 2002;359:341–345.
10. Schatzkin A, Subar AF, Thompson FE, et al. Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. *Am J Epidemiol* 2001;154:1119–1125.
11. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* 1959;22:719–748.
12. Wacholder S, Silverman DT, McLaughlin JK, et al. Selection of controls in case-control studies. II. Types of controls. *Am J Epidemiol* 1992;135:1029–1041.
13. Chen C, Weiss NS, Stanczyk FZ, et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. *Cancer Epidemiol Biomarkers Prev* 2003;12:1410–1416.
14. Pearce N. What does the odds ratio estimate in a case-control study? *Int J Epidemiol* 1993;22:1189–1192.
15. Schulz KF, Grimes DA. Case-control studies: research in reverse. *Lancet* 2002;359:431–434.
16. Rothman K. *Epidemiology: An Introduction*. New York: Oxford University Press; 2002.
17. Hennekens C, Buring J. *Epidemiology in Medicine*. Boston: Little, Brown and Company; 1987.
18. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. *N Engl J Med* 2009;360:1310–1319.
19. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. *N Engl J Med* 2012;367:203–213.
20. Yu JB, Soulos PR, Herrin J, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. *J Natl Cancer Inst* 2013;105:25–32.
21. Ma X, Wang R, Long JB, et al. The cost implications of prostate cancer screening in the Medicare population. *Cancer* 2014;120(1):96–102.
22. Rundle A, Schwartz S. Issues in the epidemiological analysis and interpretation of intermediate biomarkers. *Cancer Epidemiol Biomarkers Prev* 2003;12:491–496.
23. Shields PG. Tobacco smoking, harm reduction, and biomarkers. *J Natl Cancer Inst* 2002;94:1435–1444.
24. Hunter DJ. Gene-environment interactions in human diseases. *Nat Rev Genet* 2005;6:287–298.
25. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. *Nat Rev Genet* 2005;6:95–108.
26. Breast Cancer Association Consortum. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. *J Natl Cancer Inst* 2006;98:1382–1396.
27. Wacholder S, Chanock S, Garcia-Closas M, et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. *J Natl Cancer Inst* 2004;96:434–442.
28. Clayton DG, Walker NM, Smyth DJ, et al. Population structure, differential bias and genomic control in a large-scale, case-control association study. *Nat Genet* 2005;37:1243–1246.
29. Easton DF, Eeles RA. Genome-wide association studies in cancer. *Hum Mol Genet* 2008;17:R109–115.
30. Ahmed S, Thomas G, Ghoussaini M, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nat Genet* 2009;41:585–590.
31. Thomas G, Jacobs KB, Kraft P, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). *Nat Genet* 2009;41:579–584.
32. Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. *Nat Genet* 2008;40:310–315.
33. Le Marchand L. Genome-wide association studies and colorectal cancer. *Surg Oncol Clin N Am* 2009;18:663–668.
34. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. *Nature* 2008;452:633–637.
35. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. *Nat Genet* 2008;40:616–622.
36. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. *Nat Genet* 2009;41:986–990.
37. Kiemeney LA, Sulem P, Besenbacher S, et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. *Nat Genet* 2010;42(5):415–419.
38. Wu X, Ye Y, Kiemeney LA, et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. *Nat Genet* 2009;41:991–995.
39. Stacey SN, Sulem P, Masson G, et al. New common variants affecting susceptibility to basal cell carcinoma. *Nat Genet* 2009;41:909–914.
40. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. *Nature* 2008;452:638–642.
41. Spitz MR, Amos CI, Dong Q, et al. The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. *J Natl Cancer Inst* 2008;100:1552–1556.
42. Zheng W, Long J, Gao YT, et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. *Nat Genet* 2009;41:324–328.
43. Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. *Nat Genet* 2009;41:460–464.
44. Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. *Nat Genet* 2009;41:1122–1126.
45. Song H, Ramus SJ, Tyrer J, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. *Nat Genet* 2009;41:996–1000.
46. Stacey SN, Gudbjartsson DF, Sulem P, et al. Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. *Nat Genet* 2008;40:1313–1318.
47. Zanke BW, Greenwood CM, Rangrej J, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. *Nat Genet* 2007;39:989–994.
48. Haiman CA, Patterson N, Freedman ML, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. *Nat Genet* 2007;39:638–644.
49. Kiemeney LA, Thorlacius S, Sulem P, et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. *Nat Genet* 2008;40:1307–1312.
50. Ghoussaini M, Song H, Koessler T, et al. Multiple loci with different cancer specificities within the 8q24 gene desert. *J Natl Cancer Inst* 2008;100:962–966.
51. Harismendy O, Frazer KA. Elucidating the role of 8q24 in colorectal cancer. *Nat Genet* 2009;41:868–869.
52. Wright JB, Brown SJ, Cole MD. Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. *Mol Cell Biol* 2010;30:1411–1420.
53. Rafnar T, Sulem P, Stacey SN, et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. *Nat Genet* 2009;41:221–227.
54. Fernandez-Garcia I, Ortiz-de-Solorzano C, Montuenga LM. Telomeres and telomerase in lung cancer. *J Thorac Oncol* 2008;3:1085–1088.
55. Zienolddiny S, Skaug V, Landvik NE, et al. The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung. *Carcinogenesis* 2009;30:1368–1371.
56. Ioannidis JP, Thomas G, Daly MJ. Validating, augmenting and refining genome-wide association signals. *Nat Rev Genet* 2009;10:318–329.
57. Chung CC, Magalhaes WC, Gonzalez-Bosquet J, et al. Genome-wide association studies in cancer—current and future directions. *Carcinogenesis* 2010;31:111–120.
58. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. *Proc Natl Acad Sci U S A* 2005;102:10604–10609.
59. Dolinoy DC, Weidman JR, Waterland RA, et al. Maternal genistein alters coat color and protects Avy mouse offspring from obesity by modifying the fetal epigenome. *Environ Health Perspect* 2006;114:567–572.